Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
[Cancer Management and Research] A retrospective review sought to determine the effect of postoperative radiotherapy on patients with stage IIIA(N2) non-small cell lung cancer with EGFR mutation.
Severe acute oral mucositis in patients undergoing radiation therapy for head and neck cancer may be associated with an increased risk of developing trismus.
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Pelvic physical therapy may be more appropriate than Kegel exercises in managing post-radical prostatectomy pain and stress urinary incontinence, according to a new study.
Ann Brady suggests a way to help patients who are asked to make a decision between two difficult options.
[Breast Cancer: Targets and Therapy] In this report, the researchers review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs for this challenging-to-manage disease.
MRI-guided TULSA uses a transurethral catheter to precisely apply ultrasound and MRI-guided thermotherapy to ablate cancerous tissue within the prostate gland.
A review of the ways that a yoga practice can help patients cope with their cancer and manage the physical symptoms and side effects of treatment.
Investigators at UCSD sought to create a tool to help clinicians predict patients’ risk of persistent opioid use after treatment.
[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.
Before you discount the results of a DTC genetic test, explore your patient’s reason for undergoing the testing and consider the appropriateness of a referral for medical-grade testing.
Some experts say the talc study’s data limitations weaken its impact in the field.
[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.